The Latest Breaking News from Amgen Inc

Market sentiment was mostly unchanged on Monday, as investors await the May inflation report. Given the market uncertainties, we think investing in high-yielding dividend stocks that are part of the Dow Jones index—commonly known as the Dogs of the Dow—might the ideal strategy now. And our top choices among these…

Amgen Inc (NASDAQ: AMGN) has recently received a notice of deficiency from the Internal Revenue Service centered on 2013 to 2015. 

Amgen Inc (NASDAQ:AMGN) announced the presentation of long-term data from the CodeBreaK 100 Phase 1/2 trial of Lumakras (sotorasib) in KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). In the long-term, two-year analysis of 174 heavily pretreated patients, Lumakras demonstrated a centrally confirmed objective response rate (ORR) of 40.7%, disease control rate (DCR) of 83.7%,…

Despite volatile market conditions currently, owing in varying degrees to the Russia-Ukraine crisis and a hawkish Fed, a continuing economic rebound is still expected by many experts. With the slight easing of investor concerns, the Dow Jones Industrial Average has witnessed a solid recovery since mid-March. So, we think it…

Amgen Inc's (NASDAQ:AMGN) short percent of float has risen 123.83% since its last report. The company recently reported that it has 26.62 million shares sold short, which is 4.79% of all regular shares that are available for trading.

Truist has initiated coverage on Verastem Oncology Inc (NASDAQ:VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside. Analyst Srikripa Devarakonda notes that trading at about 2-times cash, the stock is "undervalued" given its programs in two cancers. Devarakonda adds that the Verastem base case is supported by a…

Amgen Inc (NASDAQ: AMGN) announced the presentation of 

Amgen Inc's (NASDAQ: AMGN) Q4 revenues incr

Amgen Inc's (NASDAQ:AMGN) short percent of float has risen 5.91% since last its last report. The company recently reported that it has 12.07 million shares sold short, which is 2.15% of all regular shares that are available for trading.